There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PSMA


PSMA Molecule Information

Name:Glutamate carboxypeptidase II
Target Synonym:Cell growth-inhibiting gene 27 protein;Membrane glutamate carboxypeptidase;FOLH ;Prostate-specific membrane antigen;FOLH1;Glutamate carboxypeptidase 2;N-acetylated-alpha-linked acidic dipeptidase I;FGCP;PSM;Folylpoly-gamma-glutamate carboxypeptidase;mGCP;
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:29
Lastest Research Phase:Approved

PSMA Protein Product ListCompare or Buy

PSMA Part of Bioactivity data

PSA-H82Qb-Cell-based assay
Evaluation of CAR expression

2e5 of PSMA-CAR-293 cells transfected with anti-PSMA-scFv were stained with 100μl of 1μg/mL of Biotinylated Human PSMA, His,Avitag (Cat. No. PSA-H82Qb) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routiney tested).

Cynomolgus PSMA, His TagCynomolgus PSMA, His Tag (Cat. No. PSA-C5247) ELISA bioactivity

Immobilized Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).

Cynomolgus PSMA, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) was more than 85% and the molecular weight of this protein is around 185-220 kDa verified by SEC-MALS.

Cynomolgus PSMA, His TagCynomolgus PSMA, His Tag (Cat. No. PSA-C5247) ELISA bioactivity

Immobilized Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).

PSMA Molecule Synonym Name


PSMA Molecule Background

Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily.  FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.

PSMA References

PSMA Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Capromab pendetide 111In CYT-356; CYT-356; Indium-111-CYT-356; lndium-CYT-356 Approved EUSA Pharma PROSTASCINT fda Prostate cancer CYTOGEN 1996-10-28 Prostate cancer, Diagnostic agents Details

PSMA Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MIP-1375 131-I-MIP-1375;MIP-1375 Preclinical Progenics Pharmaceutical Prostate cancer Details
CYT-500-Lu-177 CYT-500-Lu-177; 177LuCYT500 Phase Ⅰ Cytogen Prostate cancer Details
99mTc-EC-0652 EC-0652; 99mTc-EC-0652; DUPA-99mTc; EC-0652-99mTc Phase Ⅰ Novartis Prostate cancer Details
INO-5150 INO-5150 Phase Ⅰ Inovio Prostate cancer Details
INO-5401 INO-5401; INO5401 Phase Ⅱ Inovio Glioblastoma Details
[131I]MIP-1095 1095; [131I]MIP-1466; [131I]MIP-1095 Phase Ⅱ Progenics Pharmaceutical Prostate cancer Details
[18F]DCFPyL Phase Ⅲ Johns Hopkins University, Progenics Pharmaceutical, Sidney Kimmel Cancer Center Prostate cancer, Renal carcinoma Details
Df-IA2BM-Zr-89 Df-IA2BM-Zr-89; IAB2M; 89Zr-Df-IAB2M; 64Cu-NODAGA-PSMA-Mb Phase Ⅱ ImaginAb Glioma, Prostate cancer Details
Fluorine-18-CTT-1057 18F-CTT1057; CTT-1057; CTT-1057-18F; CTT-1057-F-18 Phase Ⅰ Washington University, Cancer Targeted Technology Renal cell carcinoma Details
P28z-CAR P28z-CAR Phase Ⅰ Memorial Sloan-Kettering Cancer Center, United States Department of Defense Prostate cancer Details
MDX-070 MDX-070,MDX-70 Phase Ⅱ Northwest Biotherapeutics, Medarex Prostate cancer Details
MOR-209/ES414 APVO-414; MOR-209; ES-414 Phase Ⅰ Emergent, MorphoSys Prostate cancer Details
CART-PSMA-TGFbRDN (University of Pennsylvania) Phase Ⅰ University of Pennsylvania Castration-resistant prostate cancer (CRPC) Details
Technetium Tc 99m trofolastat 99mTc-MIP1404; F-1311; MIP-1404; MP-1404 Phase Ⅲ Progenics Pharmaceutical, FUJIFILM Corporation Tumor imaging agent Details
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) Phase Ⅰ Sorrento Therapeutics Cancer Details
177Lu-capromab pendetide (Cytogen) CYT-500; 177Lu-7E11.C5.3; 177Lu-CYT-500; 7E11-C5.3-meO- DOTA-177Lu; Anti-PSMA-meO-DOTA-177Lu Phase Ⅰ Jazz Pharmaceuticals Prostate cancer, Cancer Details
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) Phase Ⅱ Shenzhen Geno-Immune Medical Institute Malignancies Details
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center Phase Ⅰ Roger Williams Medical Center Prostate cancer Details
Pasotuxizumab AMG-212; BAY-2010112; MT-112 Phase Ⅰ Amgen, Bayer Prostate cancer Details
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) Phase Not Specified Advanced Accelerator Applications Prostate cancer Details
HPN-424 HPN-424 Phase Ⅰ Harpoon Therapeutics Metastatic castration-resistant prostate cancer (mCRPC) Details
GPI-5693 GPI-5693 Phase Ⅰ Eisai Neuropathic pain, Diabetic neuropathy, Prostate cancer Details
177Lu-PSMA-R2 177Lu-PSMA-R2; 177Lu-PSMA-SR6 Phase Ⅱ Advanced Accelerator Applications Prostate cancer Details
PSMA-CART cell therapy (Shanghai Bioray Laboratory) Phase Ⅱ Shanghai Bioray Laboratory Inc, Changhai Hospital of Shanghai Castration-resistant prostate cancer (CRPC) Details
CC-1 CC-1 Phase Ⅱ The University of Tubingen, German cancer research center Squamous Cell Lung Cancer Details
68Ga-PSMA-617 68Ga-PSMA-617; 225 Ac-PSMA-617; PSMA-617-[68Ga]; Gallium-68-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; 68Ga-DOTA-PSMA-DKFZ -617 Phase Not Specified University of Heidelberg, Deutsches Krebsforschungszentrum Prostate cancer Details
ATL-101 (ATLAB) 177Lu-J591; 90Y-J591; huJ-591; J-591; Lu-177-J591; MLN-591RL; MLN-591; muJ-591 Phase Ⅱ Cornell University, Weill Cornell Medical College, BZL Biologics Prostate cancer Details
89Zr-DFO-huJ591 89Zr-DFO-J591; 89Zr-DFO-huJ591; Zr89-J591,89Zr DFO J591; 89Zr DFO huJ591; Zr89 J591 Phase Ⅱ Memorial Sloan-Kettering Cancer Center Prostate cancer Details
PSMA ADC PSMA-ADC Phase Ⅱ Progenics Pharmaceutical, PSMA Development Company, Brown University, Rhode Island Hospital, University of Texas at Dallas Prostate cancer, Glioblastoma Details
ATL-101 ATL-101; TLX-591 Phase Ⅱ Telix Pharmaceuticals, Weill Cornell Medical College, BZL Biologics Prostate cancer Details

This web search service is supported by Google Inc.